Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review

被引:6
|
作者
Mendoza-Pinto, Claudia [1 ]
Pirone, Carmelo [2 ]
van der Windt, Danielle A. [3 ]
Parker, Ben [4 ,5 ]
Bruce, Ian N. [4 ,6 ]
机构
[1] Mexican Inst Social Secur, Reg Gen Hosp CIBIOR 36, Syst Autoimmune Dis Res Unit, Puebla, Mexico
[2] Sapienza Univ Rome, Dept Internal Med, Med Specialties Rheumatol Unit, Rome, Italy
[3] Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England
[4] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Oxford Rd, Manchester, Lancs, England
[5] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Arthrit Res UK Ctr Epidemiol, Fac Biol Med & Hlth, Oxford Rd, Manchester, Lancs, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
Systemic lupus erythematosus; Mycophenolate mofetil; Systematic review; Prognosis; INTRAVENOUS CYCLOPHOSPHAMIDE; MAINTENANCE THERAPY; NEPHRITIS TREATMENT; INDUCTION TREATMENT; POLYMORPHISMS; DISEASE; ACID; PHARMACOKINETICS; AZATHIOPRINE; ASSOCIATION;
D O I
10.1016/j.semarthrit.2017.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We aimed to summarize the evidence examining factors that predict differential response to mycophenolate mofetil (MMF) in systemic lupus erythematosus (SLE). Methods: Systematic searches of randomized clinical trials (RCT) to identify predictors of the effects of MMF (moderators), and cohort studies to explore prognostic factors associated with MMF outcomes (response, relapse, or adverse events) were performed. Two reviewers independently assessed the methodological quality of RCTs using the Cochrane Collaboration risk of bias tool and cohort studies using the QUality In Prognosis Studies tool. The quality of subgroup analysis, providing evidence for moderation, was evaluated. The Grading of Recommendations Assessment, Development, and Evaluation working group approach summarized the quality of evidence (QoE), considering the risk of bias, imprecision, inconsistency, indirectness, and publication bias. Results: From 26 studies (13 from 7 RCTs and 13 cohort studies) we found low QoE evidence for Black/Hispanic race/ethnicity predicting better renal responses to MMF in lupus nephritis (LN) from one RCT. There was low QoE evidence from cohort studies that a higher baseline creatinine and membranous features on renal biopsy were associated with poorer responses in LN. There was very low QoE for other moderators or prognostic factors associated with MMF treatment outcomes. QoE from RCTs was affected by exploratory or insufficient evidence from subgroup analysis and in both study types high risk of bias, indirectness and imprecision also affected QoE. Conclusions: In SLE, evidence for predictors of response to MMF is limited and none can be recommended for use in routine clinical practice. Specific studies of predictors measured at baseline and during treatment are needed with a priori hypotheses based on preliminary evidence to date and with sufficient power to determine which factors can be employed in clinical decision making. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.
引用
收藏
页码:65 / 78
页数:14
相关论文
共 50 条
  • [31] Can we predict who will benefit from cognitive-behavioural therapy? A systematic review and meta-analysis of machine learning studies
    Vieira, Sandra
    Liang, Xinyi
    Guiomar, Raquel
    Mechelli, Andrea
    CLINICAL PSYCHOLOGY REVIEW, 2022, 97
  • [32] What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE
    Lee, H. S.
    Bae, S-C
    LUPUS, 2010, 19 (12) : 1452 - 1459
  • [33] Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
    Posalski, J. D.
    Ishimori, M. L.
    Wallace, D. J.
    Weisman, M. H.
    LUPUS, 2009, 18 (06) : 516 - 521
  • [34] Frailty May Identify Older Patients Who Do Not Benefit From Implantable Cardioverter-Defibrillators: A Systematic Review
    Chen, M.
    Orkaby, A.
    Rosenberg, M.
    Driver, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S243 - S243
  • [35] Patient Experiences of Systemic Lupus Erythematosus: Findings From a Systematic Review, Meta-Summary, and Meta-Synthesis
    Petrocchi, Valentina
    Visintini, Erica
    De Marchi, Ginevra
    Quartuccio, Luca
    Palese, Alvisa
    ARTHRITIS CARE & RESEARCH, 2022, 74 (11) : 1813 - 1821
  • [36] Dialogue: what can we learn about the relationship between systemic lupus erythematosus and haematological malignancies from linking disease registries?
    Ramsey-Goldman, Rosalind
    Bernatsky, Sasha
    Clarke, Ann
    LUPUS SCIENCE & MEDICINE, 2014, 1 (01):
  • [37] Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016
    Tektonidou, Maria G.
    Lewandowski, Laura B.
    Hu, Jinxian
    Dasgupta, Abhijit
    Ward, Michael M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) : 2009 - 2016
  • [38] Optical pre-screening in breast screening programs: Can we identify women who benefit most from limited mammography resources?
    Walter, Jane
    Loshchenov, Maxim
    Zhilkin, Vladimir
    Peake, Rachel
    Stone, Jennifer
    Lilge, Lothar
    INTERNATIONAL CONFERENCE ON BIOPHOTONICS V, 2017, 10340
  • [39] Embolic Stroke of Undetermined Source: Can We Identify Subgroups With High Risk for Atrial Fibrillation Who May Benefit From Oral Anticoagulation?
    Hankey, Graeme J.
    CIRCULATION, 2021, 144 (22) : 1747 - 1749
  • [40] Incidence and predictors of pacemaker dysfunction with unipolar ventricular lead configuration.: Can we identify patients who benefit from bipolar electrodes?
    Wiegand, UKH
    Bode, F
    Bonnemeier, H
    Tölg, R
    Peters, W
    Katus, HA
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2001, 24 (09): : 1383 - 1388